Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

PLASTICISE · Promotion of plasticity as a treatment for neurodegenerative conditions

FP7Status: CLOSED1 December 200830 November 2012EU funding €5,199,445

Neurodegenerative diseases all cause damage to the circuitry of the nervous system, with loss of connections, axons and neurons. The loss can be gradual, as in Alzheimer’s disease, rapid as in stroke, or intermediate as in the delayed neuronal loss after stroke. Following damage, the nervous system is able partially to compensate through the formation of alternative connections and pathways, a process known as plasticity. Adults are therefore able to regain considerable function after stroke, and to compensate for the synapse and cell loss of Alzheimer’s disease until it reaches a critical level. Children undergo a period of enhanced plasticity in most parts of the CNS at the end of development, known as critical periods. During these periods their ability to compensate for damage to the CNS is in many cases much greater than in adults. The overall concept behind this application is that restoration of the function in neurodegeneration can be achieved through plasticity (the formation of new functional connections, withdrawal of inappropriate connections, modulation of synaptic strength). Promoting increased plasticity in selected parts of the adult nervous system back to the level seen in children is a powerful method of enhancing recovery of function in animal models. Plasticity-promoting treatments could therefore be beneficial in a wide range of conditions that damage the CNS. The PLASTICISE project integrates scientists from four scientific areas 1) Development of methods to promote plasticity 2) Development of models of neurodegenerative disease 3) Imaging of plasticity at the macro and micro level 4) Study of recovery of function through plasticity in human patients with brain disorders. The concept that unites the partners is the belief that treatments that enhance plasticity will become one of key medications that will improve neurological function in the damaged human nervous system. The purpose of the project is to bring this moment closer.

Consortium · 16 organisations

coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

UK · €871,932

participant

Novartis Forschungsstiftung

CH · €338,930

participant

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK · €2,400

participant

D-Pharm LTD

IL · €14,400

participant

UNIVERSITE DE GENEVE

CH · €338,930

participant

KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW

NL · €301,130

participant

NOVARTIS PHARMA AG

CH · €2,400

participant

DANDO WEISS & COLUCCI LIMITED

UK · €229,500

participant

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

CH · €338,930

participant

PHARMAXON SAS

FR · €53,655

participant

University of Zurich

CH · €694,760

participant

CONSIGLIO NAZIONALE DELLE RICERCHE

IT · €338,360

participant

INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK

PL · €330,338

participant

UNIVERSITY COLLEGE LONDON

€641,060

participant

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

DE · €351,440

participant

UNIVERSITAETSKLINIKUM FREIBURG

DE · €351,280

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.